B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
CEO announces the deal on CNBC.
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.